EP0344960B1 - Dosisformen mit definiertem Wassergehalt zur gesteuerten Freigabe - Google Patents

Dosisformen mit definiertem Wassergehalt zur gesteuerten Freigabe Download PDF

Info

Publication number
EP0344960B1
EP0344960B1 EP89305209A EP89305209A EP0344960B1 EP 0344960 B1 EP0344960 B1 EP 0344960B1 EP 89305209 A EP89305209 A EP 89305209A EP 89305209 A EP89305209 A EP 89305209A EP 0344960 B1 EP0344960 B1 EP 0344960B1
Authority
EP
European Patent Office
Prior art keywords
dosage form
oral dosage
weight
alcohol
controlled release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP89305209A
Other languages
English (en)
French (fr)
Other versions
EP0344960A3 (en
EP0344960A2 (de
Inventor
Joanne Heafield
Stewart Thomas Leslie
Sandra Therese Antoinette Malkowska
Philip John Neale
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euro Celtique SA
Original Assignee
Euro Celtique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique SA filed Critical Euro Celtique SA
Priority to AT89305209T priority Critical patent/ATE83925T1/de
Publication of EP0344960A2 publication Critical patent/EP0344960A2/de
Publication of EP0344960A3 publication Critical patent/EP0344960A3/en
Application granted granted Critical
Publication of EP0344960B1 publication Critical patent/EP0344960B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Definitions

  • the present invention relates to a controlled release, oral dosage form, especially a tablet, containing a 3-alkylxanthine.
  • Controlled release pharmaceutical compositions comprising a combination of a higher aliphatic alcohol and a hydroxyalkylcellulose are known in the art and are described, for example, in EP-A-0 097 523, EP-A-0 251 459 and US-3 965 256. There is no teaching of what, if any, residual moisture content should remain in the final products.
  • a controlled release, solid, oral dosage form comprising a 3-alkylxanthine, at least one hydrophilic or hydrophobic polymer, at least one wax having a melting point between 25° and 90°C and between 3% and 10% (by weight) water.
  • Oral dosage forms according to the present invention are preferably tablets but are not spheroids, film coated spheroids or unit dosage forms (e.g. capsule, sachet, cachet) containing spheroids or film coated spheroids.
  • per cent (by weight) water refers to the water content of the oral dosage form as measured using a Karl Fischer titration method.
  • the water content of the oral dosage form is between 4% and 9% (by weight), most preferably between 4% and 8% (by weight), especially between 5% and 7% (by weight).
  • a particularly preferred oral dosage form according to this invention has a water content of about 6% (by weight).
  • the present inventors have surprisingly found that the water content of the present dosage forms has a dramatic effect on the in-vitro release rate of the active ingredient.
  • the water content of the dosage forms is below 3% (by wt)
  • the release rate is too slow.
  • the water content of the dosage forms is above 10%, the release rate is too fast.
  • the dosage forms have a water content between 3% and 10% (by wt) they (the dosage forms) are more stable over a 1-2 year period (with regard to rate of release of the active ingredient) than other equivalent dosage forms having water contents outside this range.
  • the present controlled release dosage forms contain a 3-alkylxanthine.
  • the phrase "3-alkylxanthine" in the present specification incorporates
  • the 3-alkylxanthine may be, for example, enprofylline or theobromine.
  • the 3-alkylxanthine is a 1,3-dimethylxanthine, such as acepifylline, bamifylline, bufylline, diprophylline, etamiphylline, etofylline, proxyphylline or theophylline.
  • theophylline anhydrous or hydrate
  • a salt or derivative of theophylline such as aminophylline, choline theophyllinate, theophylline monoethanolamine, theophylline sodium glycinate or theophylline calcium salicylate is particularly preferred.
  • Theophylline is the most preferred.
  • the in vitro dissolution rate of the theophylline from the present oral dosage form when measured by the USP Paddle Method at 100rpm in 900ml aqueous buffer (pH 6.5) at 37°C is preferably between 5% and 30% (by wt) release after 2 hours, between 15% and 40% (by wt) release after 4 hours, between 20% and 55% (by wt) release after 6 hours, between 25% and 65% (by wt) release after 8 hours, and between 40% and 90% (by wt) release after 12 hours.
  • Preferred doses of the 3-alkylxanthines in a controlled release dosage form according to this invention are as follows:
  • the concentration of 3-alkylxanthine in the present dosage forms will depend, amongst other factors, on the amount of xanthine to be administered.
  • the dosage forms preferably contain between 40% and 85% (by wt), especially between 50% and 80% (by wt), of the active ingredient.
  • the at least one hydrophilic or hydrophobic polymer may be chosen from such materials as gums, cellulose ethers, acrylic resins and protein derived materials. Of these polymers, the cellulose ethers, especially hydroxyalkylcelluloses and carboxyalkylcelluloses, are preferred.
  • the oral dosage form may contain between 1% and 20%, especially between 2% and 12% (by weight) of the at least one hydrophilic or hydrophobic polymer.
  • the at least one wax of the present invention must have a melting point between 25° and 90°C, preferably between 40° and 70°.
  • the at least one wax may be, for example, a polyalkylene glycol, a fatty (aliphatic) acid, a fatty (aliphatic) ester or, which is preferred, a fatty (aliphatic) alcohol, particularly a C12-C36 fatty alcohol, especially a C14-C22 fatty alcohol such as myristyl alcohol, cetyl alcohol, stearyl alcohol or cetostearyl alcohol.
  • the present dosage forms preferably contain between 4% and 40%, especially between 8% and 36%, by weight of the at least one wax.
  • One particularly suitable dosage form according to this invention comprises a 3-alkylxanthine, a water-soluble hydroxyalkyl cellulose, at least one C12-C36, preferably C14-C22, fatty alcohol and, optionally, at least one polyalkylene glycol.
  • the at least one hydroxyalkyl cellulose is preferably a hydroxy (C1 to C6) alkyl cellulose, such as hydroxypropylcellulose, hydroxypropylmethylcellulose and especially, hydroxyethyl cellulose.
  • the amount of the at least one hydroxyalkyl cellulose in the present dosage form will be determined, inter alia , by the precise rate of drug release required.
  • the dosage form contains between 1% and 20%, especially between 2% and 12% (by weight) of the at least one hydroalkyl cellulose.
  • the at least one fatty alcohol may be, for example, lauryl alcohol, myristyl alcohol or stearyl alcohol. In particularly preferred embodiments of the present dosage form, however, the at least one fatty alcohol is cetyl alcohol or cetostearyl alcohol.
  • the amount of the at least one fatty alcohol in the present dosage form will be determined, as above, by the precise rate of drug release required. It will also depend on whether at least one polyalkylene glycol is present in or absent from the dosage form. In the absence of at least one polyalkylene glycol, the dosage form preferably contains between 4% and 40%, especially between 8% and 36%, (by weight) of the at least one fatty alcohol.
  • the combined weight of the at least one fatty alcohol and the at least one polyalkylene glycol preferably constitutes between 4% and 40%, especially between 8% and 36%, (by weight) of the total dosage form weight.
  • the ratio of the at least one hydroxyalkyl cellulose to the at least one fatty alcohol/polyalkylene glycol determines, to a considerable extent, the release rate of the drug from the formulation.
  • a ratio of the at least one hydroxyalkyl cellulose to the at least one fatty alcohol/polyalkylene glycol of between 1:2 and 1:4 is preferred, with a ratio of between 1:3 and 1:4 being particularly preferred.
  • the at least one polyalkylene glycol may be, for example, polypropylene glycol or, which is preferred, polyethylene glycol.
  • the number average molecular weight of the at least one polyalkylene glycol is preferably between 1000 and 15000 especially between 1500 and 12000.
  • Another suitable controlled release dosage form would comprise a 3-alkylxanthine, an alkylcellulose (especially ethyl cellulose), a C12 to C36 fatty alcohol and, optionally, a polyalkylene glycol.
  • a controlled release dosage form according to this invention may also contain suitable quantities of other materials, e.g. diluents, lubricants, binders, granulating aids, colourants, flavourants and glidants that are conventional in the pharmaceutical art.
  • suitable quantities of other materials e.g. diluents, lubricants, binders, granulating aids, colourants, flavourants and glidants that are conventional in the pharmaceutical art.
  • the amount of water (including water of crystallisation) added during the wet granulation step is preferably between 2 and 30 times, especially between 4 and 20 times, the dry weight of the hydrophilic or hydrophobic polymer.
  • Theophylline monohydrate (330g) and hydroxyethyl cellulose (18.5g) were dry mixed.
  • Povidone (3.75g) was then dissolved in water (40ml) and the solution, together with a further 60ml of water, was added to the theophylline mixture.
  • the whole was then granulated, subsequently dried in a fluid bed drier (FBD) and then sieved through a 12 mesh screen. After sieving, the granules were again dried and sieved again, this time through a 16 mesh screen. The granules were then cooled.
  • BFD fluid bed drier
  • Cetostearyl alcohol (30g) and polyethylene glycol (PEG) 6000 (37.5g) were mixed and heated to give a molten mixture.
  • the wax/PEG 6000 mixture was then added to the granules and granulated.
  • the wax coated granules were cooled and sieved through a 16 mesh screen. Finally, the wax coated granules were blended with magnesium stearate (7.5g) and talc (7.5g) and compressed to give 1000 tablets, each having the following formulation,
  • Example 1 The procedure of Example 1 was followed to give 1000 tablets, each having the following formulation,
  • Example 1 The procedure of Example 1 was followed to give 1000 tablets, each having the following formulation,
  • Example 2 The procedure of Example 2 was followed except that the tablets had a water content (by Karl Fischer) of 8.1% (by weight of the total tablet weight).
  • Example 2 The procedure of Example 2 was followed except that the tablets had a water content (by Karl Fischer) of 9.7% (by weight of the total tablet weight).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Claims (10)

  1. Verfahren zur Herstellung einer festen, oralen Dosisform zur gesteuerten Freigabe, umfassend:
    (a) Naßgranulieren von Wasser, wenigstens einem hydrophilen oder hydrophoben Polymeren und einem 3-Alkylxanthin zur Bildung von Granulen,
    (b) Trocknen der Granulen,
    (c) Mischen der Granulen mit wenigstens einem Wachs mit einem Schmelzpunkt zwischen 25° und 90° C, und
    (d) wahlweise, Pressen und Formen der Granulen,
    wobei die Granulen zu einem solchen Ausmaß getrocknet werden, daß die feste, orale Dosisform mit gesteuerter Freigabe zwischen 3% und 10%, vorzugsweise zwischen 4% und 9%, (in Gewicht) an Wasser enthält, mit der Maßgabe, daß die orale Dosisform mit gesteuerter Freigabe keine Sphäroide, mit Film überzogene Sphäroide oder Einheitsdosisform, welche Sphäroide, oder mit Film überzogene Sphäroide enthält, ist/sind.
  2. Verfahren nach Anspruch 1, dadurch gekennzeichnet, daß der Wassergehalt zwischen 4% und 8%, vorzugsweise zwischen 5% und 7%, (in Gewicht) der oralen Dosisform beträgt.
  3. Verfahren nach Anspruch 1 oder Anspruch 2, dadurch gekennzeichnet, daß das 3-Alkylxanthin ein 1,3-Dimethylxanthin, vorzugsweise Theophyllin, umfaßt.
  4. Verfahren nach Anspruch 3, dadurch gekennzeichnet, daß die Dosisform zwischen 40% und 85%, vorzugsweise zwischen 50% und 80%, (in Gewicht) an Theophyllin enthält.
  5. Verfahren nach einem der Ansprüche 1 bis 4, dadurch gekennzeichnet, daß die Dosisform zwischen 1% und 20%, vorzugsweise zwischen 2% und 12%, (in Gewicht) von dem wenigstens einen hydrophilen oder hydrophoben Polymeren enthält.
  6. Verfahren nach einem der Ansprüche 1 bis 5, dadurch gekennzeichnet, daß das wenigstens eine hydrophile oder hydrophobe Polymere einen Celluloseether, vorzugsweise eine Hydroxyalkylcellulose oder eine Carboxyalkylcellulose, umfaßt.
  7. Verfahren nach Anspruch 6, dadurch gekennzeichnet, daß der Celluloseether Hydroxypropylcellulose, Hydroxypropylmethylcellulose oder Hydroxyethylcellulose, vorzugsweise Hydroxyethylcellulose, umfaßt.
  8. Verfahren nach einem der Ansprüche 1 bis 7, dadurch gekennzeichnet, daß die Dosisform zwischen 4% und 40%, vorzugsweise zwischen 8% und 36%, (in Gewicht) von dem wenigstens einen Wachs enthält.
  9. Verfahren nach einem der Anpsrüche 1 bis 8, dadurch gekennzeichnet, daß das wenigstens eine Wachs ein Polyalkylenglykol, eine Fettsäure, einen Pettsäureester oder einen Fettalkohol, vorzugsweise einen C₁₂-C₃₆-Fettalkohol, umfaßt.
  10. Verfahren nach Anspruch 9, dadurch gekennzeichnet, daß der Fettalkohol C₁₄-C₂₂-Fettalkohol, vorzugsweise Myristylalkohol, Stearylalkohol, Cetylalkohol oder Cetostearylalkohol, insbesondere Cetylalkohol oder Cetostearylalkohol, umfaßt.
EP89305209A 1988-06-02 1989-05-23 Dosisformen mit definiertem Wassergehalt zur gesteuerten Freigabe Expired - Lifetime EP0344960B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT89305209T ATE83925T1 (de) 1988-06-02 1989-05-23 Dosisformen mit definiertem wassergehalt zur gesteuerten freigabe.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8813064 1988-06-02
GB888813064A GB8813064D0 (en) 1988-06-02 1988-06-02 Controlled release dosage forms having defined water content

Publications (3)

Publication Number Publication Date
EP0344960A2 EP0344960A2 (de) 1989-12-06
EP0344960A3 EP0344960A3 (en) 1990-03-07
EP0344960B1 true EP0344960B1 (de) 1992-12-30

Family

ID=10637952

Family Applications (1)

Application Number Title Priority Date Filing Date
EP89305209A Expired - Lifetime EP0344960B1 (de) 1988-06-02 1989-05-23 Dosisformen mit definiertem Wassergehalt zur gesteuerten Freigabe

Country Status (19)

Country Link
US (1) US5091189A (de)
EP (1) EP0344960B1 (de)
JP (1) JPH0816060B2 (de)
KR (1) KR0136279B1 (de)
AT (1) ATE83925T1 (de)
AU (1) AU610401B2 (de)
CA (1) CA1323834C (de)
DE (1) DE68904119T2 (de)
DK (1) DK175130B1 (de)
ES (1) ES2053989T3 (de)
FI (1) FI93695C (de)
GB (2) GB8813064D0 (de)
GR (1) GR3007088T3 (de)
IE (1) IE61998B1 (de)
IL (1) IL90462A (de)
NO (1) NO176232C (de)
NZ (1) NZ229372A (de)
PT (1) PT90722B (de)
ZA (1) ZA894201B (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262115B1 (en) * 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
US5912268A (en) * 1995-05-22 1999-06-15 Alza Corporation Dosage form and method for treating incontinence
DK1685839T3 (da) 1997-12-22 2013-06-24 Euro Celtique Sa Farmaceutisk oral doseringsform omfattende en kombination af en opioidagonist og opioidantagonist
CN1204890C (zh) * 1997-12-22 2005-06-08 欧罗赛铁克股份有限公司 防止阿片样物质滥用的方法
AU1738800A (en) 1998-11-23 2000-06-13 Bonnie Davis Dosage formulations for acetylcholinesterase inhibitors
AU776666B2 (en) 2000-02-08 2004-09-16 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
CN1525851A (zh) 2001-05-11 2004-09-01 ������ҩ�����޹�˾ 抗滥用阿片样物质控释剂型
US7052706B2 (en) * 2001-06-08 2006-05-30 Nostrum Pharmaceuticals, Inc. Control release formulation containing a hydrophobic material as the sustained release agent
US7943173B2 (en) * 2001-07-18 2011-05-17 Purdue Pharma L.P. Pharmaceutical combinations of oxycodone and naloxone
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20030157168A1 (en) * 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
WO2003013525A1 (en) 2001-08-06 2003-02-20 Euro-Celtique S.A. Opioid agonist formulations with releasable and sequestered antagonist
IN192180B (de) * 2001-09-28 2004-03-06 Ranbaxy Lab
CA2479350A1 (en) * 2002-03-15 2003-09-25 Cypress Bioscience, Inc. Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes
CA2478515C (en) 2002-04-05 2010-09-28 Purdue Pharma Pharmaceutical preparation containing oxycodone and naloxone
DK1551372T3 (en) 2002-09-20 2018-07-23 Alpharma Pharmaceuticals Llc SEQUERATION SUBSTANCES AND RELATED COMPOSITIONS AND PROCEDURES
US20060003004A1 (en) * 2002-10-25 2006-01-05 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
JP2006515008A (ja) * 2003-01-28 2006-05-18 コレギウム ファーマシューティカル， インコーポレイテッド 経口投与のためのミルナシプランの多粒子状組成物
US20040202717A1 (en) * 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
TWI347201B (en) * 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
EP1604666A1 (de) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioide zur Behandlung der chronischen obstruktiven Lungenkrankheit
EA012220B1 (ru) * 2004-10-19 2009-08-28 Крка, Товарна Здравил, Д. Д., Ново Место Твёрдая фармацевтическая композиция, содержащая донепезила гидрохлорид
EP1702558A1 (de) * 2005-02-28 2006-09-20 Euro-Celtique S.A. Verfahren und Vorrichtung zur Darmtätigkeitserfassung
ZA200802602B (en) * 2005-08-24 2009-10-28 Rubicon Res Pvt Ltd Controlled release formulation
KR101486228B1 (ko) * 2006-06-19 2015-01-26 알파마 파머슈티컬스 엘엘씨 약제학적 조성물
CA2662358C (en) * 2006-09-29 2015-02-10 The Procter & Gamble Company Oral compositions containing gel networks
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
AU2008346870A1 (en) * 2007-12-17 2009-07-16 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US8623418B2 (en) * 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
KR20130105935A (ko) * 2008-07-07 2013-09-26 유로-셀티큐 에스.에이. 요폐의 치료를 위한 아편유사제 길항제의 용도
WO2010103039A1 (en) 2009-03-10 2010-09-16 Euro-Celtique S.A. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
KR20180037074A (ko) 2013-07-23 2018-04-10 유로-셀티큐 에스.에이. 장내 세균총이상을 초래하고/하거나 장내 박테리아 전위에 대한 위험을 증가시키는 질환과 통증으로 인해 고통받고 있는 환자에서 통증을 치료하는데 사용하기 위한 옥시코돈과 날록손의 조합물
CN114053235B (zh) * 2020-08-07 2023-07-18 广州白云山光华制药股份有限公司 茶碱缓释片及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3965256A (en) * 1972-05-16 1976-06-22 Synergistics Slow release pharmaceutical compositions
US4443428A (en) * 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
FR2535202B1 (fr) * 1982-11-03 1985-08-09 Fabre Sa Pierre Comprimes de theophylline a liberation controlee et leur procede de fabrication
US4743247A (en) * 1984-08-13 1988-05-10 Alza Corporation Process for manufacturing dosage form
US4753800A (en) * 1985-10-04 1988-06-28 Warner-Lambert Company Medicament adsorbates and their preparation
US4892742A (en) * 1985-11-18 1990-01-09 Hoffmann-La Roche Inc. Controlled release compositions with zero order release
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
ES2058111T3 (es) * 1986-06-10 1994-11-01 Euro Celtique Sa Composicion de liberacion controlada de dihidrocodeina.
GB8626098D0 (en) * 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
GB8628728D0 (en) * 1986-12-02 1987-01-07 Euro Celtique Sa Spheroids

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Pharmaceutical Dosage Forms : Tablets - vol. 1, H.A. Lieberman and L. Lachman (eds.), Marcel Dekker Inc., New York *
R. Voight und M. Bornschein, Lehrbuch der pharmazeutischen Technologie, 3. Aufl., Verlag Chemie, Weinheim, New York 1979, p. 172-173 *

Also Published As

Publication number Publication date
JPH0816060B2 (ja) 1996-02-21
IL90462A0 (en) 1990-01-18
NO176232C (no) 1995-03-01
EP0344960A3 (en) 1990-03-07
ES2053989T3 (es) 1994-08-01
GB8813064D0 (en) 1988-07-06
GB2219207A (en) 1989-12-06
KR0136279B1 (ko) 1998-04-25
CA1323834C (en) 1993-11-02
NO892229D0 (no) 1989-06-01
DK266889A (da) 1989-12-03
DE68904119D1 (de) 1993-02-11
IL90462A (en) 1993-01-31
GR3007088T3 (de) 1993-07-30
PT90722A (pt) 1989-12-29
IE61998B1 (en) 1994-12-14
FI93695B (fi) 1995-02-15
IE891744L (en) 1989-12-02
DE68904119T2 (de) 1993-06-09
NO892229L (no) 1989-12-04
PT90722B (pt) 1994-11-30
DK175130B1 (da) 2004-06-14
GB2219207B (en) 1992-01-02
DK266889D0 (da) 1989-06-01
JPH0225420A (ja) 1990-01-26
FI93695C (fi) 1995-05-26
FI892664L (fi) 1989-12-03
ZA894201B (en) 1990-03-28
AU610401B2 (en) 1991-05-16
KR900000077A (ko) 1990-01-30
US5091189A (en) 1992-02-25
GB8911629D0 (en) 1989-07-05
ATE83925T1 (de) 1993-01-15
FI892664A0 (fi) 1989-06-01
AU3512789A (en) 1989-12-07
NZ229372A (en) 1991-07-26
NO176232B (no) 1994-11-21
EP0344960A2 (de) 1989-12-06

Similar Documents

Publication Publication Date Title
US5091189A (en) Controlled release dosage forms having a defined water content
EP0270305B1 (de) Spheroiden
US5266331A (en) Controlled release oxycodone compositions
US4990341A (en) Controlled release hydromorphone composition
HUE025210T2 (en) DPP IV inhibitor preparations
CZ288545B6 (cs) Stabilizovaná farmaceutická kompozice na bázi kyseliny (E)-3,5-dihydroxy-7-[4´-4´´-fluorfenyl-2´-cyklopropylchinolin-3´-yl]-6-heptenové
US4327080A (en) Novel Bendroflumethiazide formulations and method
EP0571973B1 (de) Tablette zur langsamen Freisetzung von Natriumvalproat
IE64659B1 (en) Pimobendan compositions
CA2532093A1 (en) Solid formulation
KR19990023194A (ko) 라세미화 반응에 대하여 안정화된 실란세트론 제제
CZ57793A3 (en) Hard capsules of cytarabia-ocphosphate
JPH07112934A (ja) ペントキシフィリンの徐放化製剤およびその製法
PT97970A (pt) Processo para a preparacao de composicoes melhoradas de acido 5-(2,5-dimetilfenoxi)-2,2-dimetilpentanoico (gemefibrozil)
AU617949B2 (en) A method for producing a solid pharmaceutical preparation
EP1104673A1 (de) Ein Hydrogencarbonat enthaltendes sprengmittelfreies Arzneimittel
JP2002226371A (ja) プラバスタチンナトリウムの錠剤
HK1088560A (en) Solid pharmaceutical preparation
GB2191398A (en) Dihydrocodeine dosage forms

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE ES FR GB GR IT LI NL SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE ES FR GB GR IT LI NL SE

17P Request for examination filed

Effective date: 19900706

17Q First examination report despatched

Effective date: 19910801

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE ES FR GB GR IT LI NL SE

REF Corresponds to:

Ref document number: 83925

Country of ref document: AT

Date of ref document: 19930115

Kind code of ref document: T

ITF It: translation for a ep patent filed
REF Corresponds to:

Ref document number: 68904119

Country of ref document: DE

Date of ref document: 19930211

ET Fr: translation filed
REG Reference to a national code

Ref country code: GR

Ref legal event code: FG4A

Free format text: 3007088

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2053989

Country of ref document: ES

Kind code of ref document: T3

EAL Se: european patent in force in sweden

Ref document number: 89305209.2

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20080421

Year of fee payment: 20

Ref country code: DE

Payment date: 20080425

Year of fee payment: 20

Ref country code: ES

Payment date: 20080512

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20080410

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20080506

Year of fee payment: 20

Ref country code: IT

Payment date: 20080422

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20080421

Year of fee payment: 20

Ref country code: NL

Payment date: 20080418

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20080414

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20080425

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20080416

Year of fee payment: 20

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

BE20 Be: patent expired

Owner name: S.A. *EUROCELTIQUE

Effective date: 20090523

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20090522

EUG Se: european patent has lapsed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20090525

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20090523

NLV7 Nl: ceased due to reaching the maximum lifetime of a patent

Effective date: 20090523

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20090525

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20090522